A probiotic mixed preparation with anti-influenza ability and its application

A probiotic and anti-influenza technology, applied in the field of microorganisms, can solve problems such as obvious side effects and achieve great application prospects

Active Publication Date: 2020-07-03
JIANGNAN UNIV +1
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, it may be possible to start with gut microbes and try to find new drugs or methods for the prevention and treatment of influenza, so as to overcome the shortcomings of existing drugs and treatment methods with obvious side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A probiotic mixed preparation with anti-influenza ability and its application
  • A probiotic mixed preparation with anti-influenza ability and its application
  • A probiotic mixed preparation with anti-influenza ability and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-1

[0065] Example 1-1: Screening and identification of mucosal lactobacilli

[0066] 1. Screening

[0067] Take human feces as the sample, after pretreatment, store the sample in about 20% glycerol in a -80°C refrigerator, take it out and thaw it, mix the sample and add 0.5mL sample to 4.5mL to contain 0.05% cysteine 0.9% normal saline for gradient dilution, select the appropriate gradient dilution and spread it on the MRS plate added with 0.05% cysteine, incubate at 37°C for 48h, pick typical colonies and streak them on the MRS plate for purification, pick A single colony was taken and transferred to liquid MRS medium (containing 0.05% cysteine) for enrichment and preserved in 30% glycerol to obtain strain CCFM1025 and strain F1.

[0068] 2. Identification

[0069] The genomes of CCFM1025 and F1 were extracted, the 16S rDNA of CCFM1025 and F1 were amplified and sequenced (Shanghai Sangon Bioengineering Co., Ltd.), and the sequences were compared in GenBank. The results showed ...

Embodiment 1-2

[0070] Embodiment 1-2: the cultivation of mucosal lactobacillus

[0071] Lactobacillus mucosae CCFM1025 was inserted into MRS solid medium (containing 0.05% cysteine) and cultured at 37°C for 48 hours, and its colonies were observed under a microscope, and the colonies were found to be Round and rough, transparent, and its bacteria are short rod-shaped.

[0072] Lactobacillus mucosae (Lactobacillus mucosae) CCFM1025 was inserted into MRS medium (containing 0.05% cysteine) and cultured at 37°C for 48 hours, and the growth curve was made. It is a heterofermentation that produces acid and gas from glucose.

[0073] Lactobacillus mucosae (Lactobacillus mucosae) CCFM1025 was inserted into MRS medium (containing 0.05% cysteine) and cultured at 10, 15, 20, 25, 30, 35, 40, 45, and 50°C for 48 hours to observe its Growth status: It grows well at 20-35°C, and it can still grow at 45°C, but it hardly grows at 15°C or below 15°C or 50°C.

[0074] Lactobacillus mucosae (Lactobacillus mu...

Embodiment 1-3

[0075] Example 1-3: Effects of mucosal lactobacilli on the body weight of influenza mice

[0076] Take 40 healthy ICR female mice with a body weight of 20-24g, and divide them into 5 groups randomly, and the 5 groups are respectively named: blank control group (Control), influenza model group (Model), and ribavirin drug treatment group (Treatment). , Lactobacillus mucosal intervention group (CCFM1025) administered intragastrically with Lactobacillus CCFM1025, Lactobacillus mucosal intervention group (F1) administered intragastrically with Lactobacillus F1, 8 rats in each group.

[0077]Two weeks before the experiment, the Lactobacillus Lactobacillus intervention group (CCFM1025) was intragastrically administered 10 times a day. 9 Lactobacillus mucous membranes CCFM1025 bacterial suspension dilution of CFU bacteria amount, Lactobacillus mucous membranes F1 intervention group (F1) gavaged the same amount of Lactobacillus mucous membranes F1 bacterial suspension dilution, and the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a probiotic mixed preparation with anti-influenza ability and an application thereof, belonging to the technical field of microbes and the technical field of medicine. This probiotic mixed preparation has the effect of anti-influenza, which is specifically reflected in: (1) significantly improving the degree of weight loss of influenza mice; (2) significantly improving the blood indicators of influenza mice; (3) significantly improving the inflammation of respiratory tract infection in influenza mice (4) Significantly reduce the viral load in the lungs of influenza mice (that is, significantly inhibit the replication and proliferation of influenza virus in influenza mice); (5) significantly enhance the expression of antiviral protein MxA in the lungs of influenza mice, Therefore, the probiotic mixed preparation has great application prospects in the preparation of products for preventing and / or treating atopic dermatitis and even preventing and / or treating influenza.

Description

technical field [0001] The invention relates to a probiotic mixed preparation with anti-influenza ability and application thereof, belonging to the technical field of microorganisms and the technical field of medicine. Background technique [0002] Influenza is often a pandemic in autumn and winter, mainly caused by influenza virus. Influenza viruses can be divided into three types: influenza A virus, influenza B virus, and influenza C virus. Human influenza is mainly caused by influenza A virus and influenza B virus. Generally, animal influenza viruses do not infect humans, and human influenza viruses do not infect animals, but pigs are an exception. Pigs can be infected with both avian influenza virus and human influenza virus, but they are mainly infected with avian influenza virus. However, once they are infected with avian influenza virus, they can easily infect humans, causing human influenza pandemics, for example, 1819-1920 The "Spanish flu" that occurred in [00...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N1/20A23L33/135A61K35/745A61K35/747A61P31/16C12R1/225C12R1/01
CPCA61P31/16A23L33/135C12N1/20A61K2035/11A23V2002/00A23V2400/11A23V2400/519A23V2200/318A23V2200/30A61K35/745A61K35/747A61K2035/115A61K35/20A61K2300/00
Inventor 陈卫陆文伟翟齐啸刘馨阳赵建新杭锋张灏
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap